Enovix Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; the supplied filing does not provide a separate Q4 income statement.
Business context and strategic developments
Enovix develops and manufactures lithium-ion batteries using a proprietary architecture designed to enable silicon-only active anodes. The company remains in early commercialization and is working to scale production. In 2023 it shifted Fab1 in Fremont toward product development, selected Malaysia for high-volume manufacturing at Fab2, and acquired Korean battery maker Routejade, adding electrode-coating and battery-pack capabilities.
Routejade was acquired on October 31 for approximately $15.4 million in cash and 5.9 million Enovix shares, valued at approximately $52.8 million. The acquisition contributed about $7.3 million of 2023 revenue.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $7.6 million | $6.2 million |
| Cost of revenue | $63.1 million | $23.2 million |
| Gross loss | $55.4 million | $17.0 million |
| Operating expenses | $174.8 million | $114.9 million |
| Operating loss | $230.3 million | $132.0 million |
| Net loss attributable to Enovix | $214.1 million | $51.6 million |
| Net loss per share, basic | $1.35 | $0.34 |
| Net cash used in operating activities | $104.6 million | $82.7 million |
| Capital expenditures | $61.8 million | $36.2 million |
Revenue increased 23%, but 2023 revenue primarily reflected Routejade product sales; 2022 revenue was primarily engineering-service revenue. Gross margin remained deeply negative (approximately negative 725% in 2023 versus negative 275% in 2022). Enovix reported an accumulated deficit of $598.8 million.
At year-end, cash and cash equivalents were $233.1 million, short-term investments $73.7 million, and restricted cash $2.0 million; management reported combined cash, cash equivalents, restricted cash, and short-term investments of $308.8 million. Working capital was $262.2 million. Cash, cash equivalents, and restricted cash declined by $87.9 million during the year.
Gross principal debt was $175.8 million, including $172.5 million of unsecured 3.0% convertible senior notes due May 2028 and Routejade loans. The balance sheet reported $169.1 million of long-term debt, net, and $5.9 million of short-term debt. The notes’ initial conversion price is $15.61 per share.
Material changes and unusual items
- Cost of revenue rose 171%, including increased labor, scrap and absorption costs, inventory reserves, and depreciation. Enovix recorded an $11.7 million inventory reserve and said some products were being sold below manufacturing cost.
- Operating expenses rose 52%. FY2023 included substantial stock-based compensation, including $21.1 million related to equity-award modifications following management departures.
- The Fab1 realignment generated $3.0 million of restructuring costs. It also triggered approximately $18.5 million of accelerated depreciation in Q4 2023, with a further approximately $18.5 million expected in Q1 2024.
- Other income included a $6.2 million gain from a decrease in the fair value of warrant liabilities, versus a $75.2 million gain in FY2022. FY2023 also included $14.1 million of interest income and $4.5 million of interest expense.
Outlook, management commentary, and risks
Management expects cash resources to fund requirements for the next 12 months from the filing date, assuming no significant R&D delays or deterioration in capital efficiency. It expects operating losses and spending to continue, with costs and capital expenditures increasing as Fab2 is built out and production ramps. Additional financing may be needed for longer-term operations and expansion.
Enovix planned to install its first Gen2 manufacturing line and an Agility pilot line in Malaysia in 2024. Management estimates a Gen2 line could produce at least 9.5 million batteries annually at 80% overall equipment effectiveness, depending on cell size; customers may require several months to qualify a line before accepting high-volume output. The company also planned to begin sampling its EX-1M high-cycle-life smartphone batteries in Q2 2024 and reported confidence in achieving a 1,000-cycle target.
Key risks include manufacturing yield, throughput, equipment reliability and unit cost; customer qualification delays and customer concentration; dependence on suppliers and the Malaysian manufacturing partner YBS; continued losses and potential capital needs; product performance, safety and warranty exposure; and competition. One South Korean military subcontractor accounted for approximately 75% of FY2023 revenue. The filing also describes a $70 million YBS-related term loan and an Enovix deposit arrangement with OCBC; the year-end status and future collateral requirements merit close review.
A securities class action concerning statements about manufacturing scale-up and equipment testing was dismissed on January 30, 2024, with leave to amend. The filing also reports employment-related lawsuits. Management stated that it did not expect the outstanding legal matters to have a material adverse effect, while noting outcomes remain uncertain.
The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting. Routejade was excluded from the year-end internal-control assessment during the permitted post-acquisition integration period.
Important facts for investors to verify
- Fab2 construction, Gen2 and Agility line installation, actual yield and throughput, and customer qualification progress against the 2024 plans.
- Whether the reported cash balance and expected funding runway remain adequate after planned capital spending, operating losses, and any OCBC collateral deposits; clarify the $70 million deposit’s precise year-end status.
- Revenue mix and customer concentration after Routejade’s inclusion, including the exposure to the customer responsible for approximately 75% of FY2023 revenue.
- Progress toward lowering manufacturing costs, reducing inventory reserves, and improving gross margins from sharply negative levels.
- Conversion, dilution, and potential cash-settlement implications of the $172.5 million convertible notes, as well as the $15.61 initial conversion price.
- Developments in the securities and employment litigation, and integration of Routejade’s controls into Enovix’s FY2024 assessment.